Free Trial
NASDAQ:CNTG

Centogene (CNTG) Stock Price, News & Analysis

$0.41
+0.04 (+10.95%)
(As of 06/18/2024 ET)
Today's Range
$0.36
$0.43
50-Day Range
$0.36
$0.65
52-Week Range
$0.34
$1.98
Volume
273,389 shs
Average Volume
54,275 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CNTG stock logo

About Centogene Stock (NASDAQ:CNTG)

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

CNTG Stock Price History

CNTG Stock News Headlines

Elon Musk: THIS will be bigger than Tesla
If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.
Elon Musk: THIS will be bigger than Tesla
If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.
CENTOGENE Receives Nasdaq Non-Compliance Notice
Centogene (NASDAQ: CNTG)
Centogene NV: CENTOGENE Explores Strategic Alternatives
Centogene Explores Strategic Alternatives, Incl. Sale
Centogene Announces Receipt Of Nasdaq Notice Of Delisting
CENTOGENE Explores Strategic Alternatives
CENTOGENE Announces Preliminary Full Year 2023 Revenue
See More Headlines
Receive CNTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/24/2021
Today
6/19/2024
Next Earnings (Estimated)
8/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CNTG
Fax
N/A
Employees
444
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$52.53 million
Book Value
($1.01) per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.68
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Ms. Kim Stratton (Age 62)
    CEO & Member of Management Board
    Comp: $1.83M
  • Mr. Jose Miguel Coego Rios (Age 50)
    CFO, Legal & IT and Member of Management Board
    Comp: $898.5k
  • Dr. Peter Bauer M.D. (Age 54)
    Interim MD, Chief Medical & Genomic Officer and Member of Management Board
    Comp: $381.67k
  • Dr. Andrin Oswald M.D. (Age 52)
    Ph.D., Advisor
    Comp: $941.75k
  • Mr. Ian Rentsch (Age 48)
    Chief Commercial Officer & GM of Pharma

CNTG Stock Analysis - Frequently Asked Questions

How have CNTG shares performed in 2024?

Centogene's stock was trading at $1.20 at the beginning of 2024. Since then, CNTG shares have decreased by 66.2% and is now trading at $0.4052.
View the best growth stocks for 2024 here
.

Are investors shorting Centogene?

Centogene saw a increase in short interest in May. As of May 31st, there was short interest totaling 137,700 shares, an increase of 402.6% from the May 15th total of 27,400 shares. Based on an average daily trading volume, of 161,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.3% of the company's shares are short sold.
View Centogene's Short Interest
.

When is Centogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our CNTG earnings forecast
.

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) posted its quarterly earnings results on Wednesday, November, 24th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.49. The firm had revenue of $35.60 million for the quarter, compared to the consensus estimate of $31.91 million. During the same quarter in the prior year, the company earned ($0.32) EPS.

What other stocks do shareholders of Centogene own?
When did Centogene IPO?

Centogene (CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Evercore ISI served as the underwriters for the IPO and Baird and BTIG were co-managers.

Who are Centogene's major shareholders?

Centogene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.00%).

How do I buy shares of Centogene?

Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTG) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners